When to start HAART for the treatment of HIV infection

Lancet Infectious Diseases

Volumn 7, Issue 1, 2007, Pages 5-6

  Wang, Cunlin ^a   Masho, Saba ^b   Nixon, Daniel ^b   Nelson, Kenrad E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; DISEASE SEVERITY; DISEASE TRANSMISSION; EUROPE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ABUSE; KIDNEY DISEASE; LETTER; LIVER DISEASE; MORTALITY; PRIORITY JOURNAL; UNITED STATES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; TIME FACTORS;

EID: 33845479689     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(06)70664-8     Document Type: Letter

References (15)

1. Wood E., Hogg R., Harrigan P., and Montaner J. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis 5 (2005) 407-414
2. Sterne J, May M, Costagliola D. Estimating the optimum CD4 threshold for starting HAART in ART-naive HIV-infected individuals. 13th Conference on Retroviruses and Opportunisitic Infections; Denver, CO, USA; Feb 5-8, 2006. Abstract S87-525.
3. Jaen A, Esteve A, Montouliu, et al. When is the optimal moment to start HAART in HIV infected patients from PISCIS cohort study (Spain)? The 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; Sept 27-30, 2006. Abstract H-1059.
4. Wang C., Vlahov D., Galai N., et al. Mortality in HIV-seropositive versus - seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 190 (2004) 1046-1054
5. Weber R., Sabin C., Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166 (2006) 1632-1641
6. Wang C., Vlahov D., Galai N., et al. The effect of HIV infection on overdose mortality. AIDS 19 (2005) 935-942
7. van Asten L., Zangerle R., Hernandez Aguado I., et al. Do HIV disease progression and HAART response vary among injecting drug users in Europe?. Eur J Epidemiol 20 (2005) 795-804
8. Lange C., Lederman M., Medvik K., et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 17 (2003) 2015-2023
9. D'Amico R., Yang Y., Mildvan D., et al. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol 25 (2005) 106-115
10. Keruly J, Moore R. Increase in CD4+ cell count out to five years in persons with sustained virologic suppression. 13th Conference on Retroviruses and Opportunisitic Infections; Denver, CO, USA; Feb 5-8, 2006. Abstract S87-529.
11. El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART study. 13th Conference on Retroviruses and Opportunisitic Infections; Denver, CO, USA; Feb 5-8, 2006. Abstract S23-106LB.
12. Lichtenstein K, Armon C, Buchacz K. Early, uninterrupted ARTI is associated with improved outcomes and fewer toxicities in the HIV Outpatient Study (HOPS). 13th Conference on Retroviruses and Opportunisitic Infections; Denver, CO, USA; Feb 5-8, 2006. S132-769.
13. Castilla J., Del Romero J., Hernando V., Marincovich B., Garcia S., and Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 40 (2005) 96-101
14. Deeks S. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients. Lancet 367 (2006) 711-713
15. Ananworanich J., Gayet-Ageron A., Le Braz M., et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 368 (2006) 459-465